Opendata, web and dolomites

BRCA-ERC SIGNED

Understanding cancer development in BRCA 1/2 mutation carriers for improved Early detection and Risk Control

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BRCA-ERC project word cloud

Explore the words cloud of the BRCA-ERC project. It provides you a very rough idea of what is the project "BRCA-ERC" about.

cohort    clinician    overtaking    cervical    team    interdisciplinary    chronic    scientific    net    brca1    cell    uncover    breakthrough    core    mortality    screening    medical    recent    reset    controls    cancers    cardiovascular    pioneering    diseases    fundamental    mutations    samples    efficacy    predictors    risk    ovarian    normal    mutation    groups    cancer    epigenetic    preventative    human    computational    establishing    germline    breast    principles    multicellular    multifactorial    brca    women    consequently    consequence    extremely    centered    ideally    origin    hypothesis    advocacy    buccal    possibly    epigenome    functionalists    mechanistically    neutralise    largely    immunologists    medicine    linked    assembled    patient    direct    applicable    disease    fatal    biologists    blood    cells    monitor    demonstrates    placed    trigger    identity    scientists    lack    powerful    carriers    effect    autonomous    reducing    tissues    newly    surgery    re    distant    initiating    organs    outcome   

Project "BRCA-ERC" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITY COLLEGE LONDON 

Organization address
address: GOWER STREET
city: LONDON
postcode: WC1E 6BT
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 2˙497˙841 €
 EC max contribution 2˙497˙841 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-ADG
 Funding Scheme ERC-ADG
 Starting year 2017
 Duration (year-month-day) from 2017-09-01   to  2022-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY COLLEGE LONDON UK (LONDON) coordinator 2˙264˙589.00
2    UNIVERSITY COLLEGE LONDON HOSPITALSNHS FOUNDATION TRUST UK (LONDON) participant 233˙251.00

Map

 Project objective

Recent evidence demonstrates that cancer is overtaking cardiovascular disease as the number one cause of mortality in Europe. This is largely due to the lack of preventative measures for common (e.g. breast) or highly fatal (e.g. ovarian) human cancers. Most cancers are multifactorial in origin. The core hypothesis of this research programme is that the extremely high risk of BRCA1/2 germline mutation carriers to develop breast and ovarian cancer is a net consequence of cell-autonomous (direct effect of BRCA mutation in cells at risk) and cell non-autonomous (produced in distant organs and affecting organs at risk) factors which both trigger epigenetic, cancer-initiating effects. The project’s aims are centered around the principles of systems medicine and built on a large cohort of BRCA mutation carriers and controls who will be offered newly established cancer screening programmes. We will uncover how ‘cell non-autonomous’ factors work, provide detail on the epigenetic changes in at-risk tissues and investigate whether these changes are mechanistically linked to cancer, study whether we can neutralise this process and measure success in the organs at risk, and ideally in easy to access samples such as blood, buccal and cervical cells. In my Department for Women’s Cancer we have assembled a powerful interdisciplinary team including computational biologists, functionalists, immunologists and clinician scientists linked to leading patient advocacy groups which is extremely well placed to lead this pioneering project to develop the fundamental understanding of cancer development in women with BRCA mutations. To reset the epigenome, re-establishing normal cell identity and consequently reducing cancer risk without the need for surgery and being able to monitor the efficacy using multicellular epigenetic outcome predictors will be a major scientific and medical breakthrough and possibly applicable to other chronic diseases.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BRCA-ERC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BRCA-ERC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

Cu4Peroxide (2020)

The electrochemical synthesis of hydrogen peroxide

Read More  

CHIPTRANSFORM (2018)

On-chip optical communication with transformation optics

Read More  

CohoSing (2019)

Cohomology and Singularities

Read More